Comparative Pharmacology
Head-to-head clinical analysis: AMBODRYL versus PROMETHAZINE W DEXTROMETHORPHAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBODRYL versus PROMETHAZINE W DEXTROMETHORPHAN.
AMBODRYL vs PROMETHAZINE W/ DEXTROMETHORPHAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine (H1-receptor antagonist) with anticholinergic and sedative properties.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist and antiemetic; dextromethorphan is a non-opioid antitussive that acts as an NMDA receptor antagonist and sigma-1 receptor agonist.
10-20 mg intramuscularly or intravenously every 4-6 hours as needed, up to a maximum of 80 mg/day.
5 mL (containing promethazine 6.25 mg and dextromethorphan 15 mg) orally every 4-6 hours as needed, not to exceed 30 mL (promethazine 37.5 mg, dextromethorphan 90 mg) per 24 hours.
None Documented
None Documented
Terminal elimination half-life 12-15 hours in adults; prolonged to 20-30 hours in hepatic impairment.
Promethazine: 9-16 h; dextromethorphan: 3-5 h (extensive metabolizers), 30-50 h (poor metabolizers). Clinical context: dosing interval typically 4-6 h for dextromethorphan; promethazine accumulates with repeated dosing.
Primarily renal (70-80% as metabolites, 20-30% unchanged); biliary/fecal excretion accounts for 15-20%.
Renal: promethazine ~6% unchanged, dextromethorphan ~0.5% unchanged; metabolites primarily renal. Biliary/fecal: minor routes for both.
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic